over 3 years ago • 2 mins
Apparently Moderna never listened to Nancy as a kid: the American biotech’s shares got totally high on Wednesday after its encouraging coronavirus vaccine trial results were published late on Tuesday 💉
Let’s start with a disclaimer: it’s still early days for Moderna’s potential vaccine. But even so, it’s said to have produced a “robust” immune response in all 45 human patients that took part in its early-stage trial. More specifically, the vaccine produced antibodies that could potentially neutralize COVID-19 and give participants at least some protection from the virus. Another disclaimer: there are still several unknowns, including how long that protection might last.
Moderna previously announced plans to enrol 30,000 new participants to take part in late-stage vaccine trials later this month. And now – given the early excitement around its initial trials – investors, governments, and exhausted parents worldwide will be watching the results even more closely 👀
Moderna’s stock initially rose almost 20% on Wednesday, suggesting investors were hopeful this vaccine will be “the one”. That’s despite all the unknowns of drug development and the stiff competition in the market: hundreds of potential vaccines are in development, after all. News even broke on Wednesday that the University of Oxford’s rival vaccine – set to be produced by AstraZeneca – might be even more effective than Moderna’s 🤔 So investors who aren’t brave enough to back a single winner might be inclined to put all the vaccine-developing companies into a single basket and buy that instead.
Even economists’ and companies’ most positive forecasts are heavily caveated with the looming risk of a coronavirus resurgence. But a vaccine could negate that risk and set the global stage for a much-hoped-for – yet increasingly unlikely – V-shaped recovery of both economies and company earnings alike. And that might be why stocks the world over got a nice boost from Moderna’s update.
Disclaimer: These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment advisor.